Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (NASDAQ:PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).
Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the U.S. and supported by ongoing geographic expansion. Full-year 2025 operating expenses are expected to be within the previously communicated range of US$304 to US$308 million, underscoring our commitment to cost discipline. Looking ahead, we anticipate sustained revenue growth and continued advancement of our clinical pipeline in 2026. We plan to report complete fourth quarter and full year 2025 financial results on March 12, 2026.
The Investor Day agenda will include a comprehensive update on our advancing pipeline, including leniolisib in Phase II proof of concept clinical trials for primary immunodeficiencies (PIDs) with immune dysregulation, including Common Variable Immunodeficiency (CVID) with immune dysregulation, as well as KL1333 in a pivotal clinical study (FALCON) for mitochondrial DNA (mtDNA)-driven mitochondrial disease. We will also present our 2026 financial guidance, highlighting anticipated revenue drivers and operating expense expectations.
The program will feature presentations from leading clinical experts:
- Jocelyn Farmer, MD, PhD, Lahey Hospital & Medical Center — an internationally recognized authority on immune dysregulation and CVID
- Amel Karaa, MD, Massachusetts General Hospital, Harvard Medical School — an internationally recognized authority on mitochondrial medicine
These key opinion leaders will discuss the evolving understanding of immune dysregulation in PIDs and the unmet need in mtDNA-related mitochondrial disease, providing important clinical context for our development programs.